NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NTLA

Intellia Therapeutics Inc

Jul 14 • 04:00PM ET

11.95

Dollar change +0.41
Percentage change 3.60	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK ARKG IWM VTI XBI VB VXF IWN VBK IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.23	Insider Own	5.95%	Shs Outstand	103.54M	Perf Week	16.59%
Market Cap	1.24B	Forward P/E	-	EPS next Y	-3.84	Insider Trans	-0.17%	Shs Float	97.42M	Perf Month	42.77%
Enterprise Value	853.32M	PEG	-	EPS next Q	-1.02	Inst Own	92.22%	Short Float	30.93%	Perf Quarter	76.51%
Income	-525.91M	P/S	27.16	EPS this Y	20.79%	Inst Trans	2.49%	Short Ratio	6.62	Perf Half Y	-0.58%
Sales	45.57M	P/B	1.59	EPS next Y	7.70%	ROA	-46.84%	Short Interest	30.13M	Perf YTD	2.49%
Book/sh	7.53	P/C	2.46	EPS next 5Y	30.65%	ROE	-57.92%	52W High	28.18 -57.59%	Perf Year	-48.38%
Cash/sh	4.86	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-61.12%	52W Low	5.90 102.54%	Perf 3Y	-81.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	77.46%	Volatility	7.50% 7.36%	Perf 5Y	-50.27%
Dividend TTM	-	EV/Sales	18.73	EPS Y/Y TTM	2.57%	Oper. Margin	-1173.09%	ATR (14)	0.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.90	Sales Y/Y TTM	-13.37%	Profit Margin	-1154.10%	RSI (14)	68.52	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	4.90	EPS Q/Q	1.81%	SMA20	17.70%	Beta	2.29	Target Price	36.64
Payout	-	Debt/Eq	0.15	Sales Q/Q	-42.54%	SMA50	31.97%	Rel Volume	0.62	Prev Close	11.53
Employees	403	LT Debt/Eq	0.10	Earnings	May 08 BMO	SMA200	3.07%	Avg Volume	4.55M	Price	11.95
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.00% 30.18%	Trades		Volume	2,830,931	Change	3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144

Show Previous Ratings

Today 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-08-25 12:54PM	The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. (Barchart) +8.49%
Jul-07-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data (Insider Monkey)
08:03AM	Loading…
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
Jun-23-25 01:41AM	Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress (Insider Monkey)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily) +6.92%
01:32PM	Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential (Insider Monkey)
05:44AM	FDA clears CSLs swelling disease drug; Regeneron loses 23andMe auction (BioPharma Dive)
Jun-15-25 10:45AM	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.73%
10:58AM	Loading…
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
09:55AM	How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -7.79%
05:56AM	Intellia stock dips following safety event in Phase III gene therapy trial (Clinical Trials Arena)
May-29-25 08:30PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.88%
08:18AM	Intellia stock tumbles on safety concerns (Investing.com)
07:16AM	Intellia filing spurs safety concerns over CRISPR drug (BioPharma Dive)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks) +6.59%
May-18-25 07:25AM	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting (GlobeNewswire)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +5.26%
May-15-25 09:55AM	Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? (Zacks)
May-09-25 12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
09:08AM	Loading…
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:12AM	Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-08-25 05:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.58%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
11:57AM	Intellia Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.10%
08:40AM	CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Apr-30-25 10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +8.17%
Apr-29-25 09:55AM	Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet (Zacks)
Apr-23-25 09:50AM	Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation (PR Newswire)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +9.54%
Apr-11-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +9.45%
Apr-09-25 09:42AM	Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.74%
Apr-04-25 01:42PM	Intellia Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information NTLA (GlobeNewswire)
07:28AM	Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN (Clinical Trials Arena)
Apr-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.62%
12:40PM	IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility (Pharmaceutical Technology)
07:30AM	Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Apr-01-25 12:41PM	Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? (Insider Monkey) -6.40%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks) -11.90%
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
Mar-26-25 07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-21-25 11:25AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-05-25 09:34AM	Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls (The Fly)
Mar-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-25 06:01AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -7.09%
02:10AM	Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
01:17AM	Q4 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-26-25 08:56PM	Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) -6.95%
Feb-24-25 10:00AM	2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street (Motley Fool) -5.42%
Feb-20-25 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:57AM	Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates (GlobeNewswire)
Feb-18-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +7.76%
Feb-14-25 02:08PM	Intellia Therapeutics (NTLA): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey) +11.00%
09:55AM	Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect? (Zacks)
Feb-06-25 08:10PM	Intellia Therapeutics Inc. (NTLA): Among Cathie Woods Top Stock Picks for 2025 (Insider Monkey)
Feb-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.25%
Jan-23-25 09:14AM	Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema (Clinical Trials Arena)
Jan-22-25 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (GlobeNewswire) +10.76%
05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-13-25 03:00AM	Intellia slashes workforce by 27% to focus on late stage CRISPR candidates (Pharmaceutical Technology)
Jan-11-25 10:20AM	Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital (TipRanks)
07:36AM	Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo (TipRanks)
Jan-10-25 01:30PM	Why Is Intellia Therapeutics Stock Trading Lower On Friday? (Benzinga) -15.14%
03:58AM	Intellia to stop work on rare disease therapy, lay off staff (BioPharma Dive)
Jan-09-25 04:00PM	Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Jan-06-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.52%
Dec-30-24 03:51PM	Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 03 '25	Sale	12.18	1,372	16,711	45,640	Jan 07 05:23 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '25	Sale	12.18	7,074	86,161	74,497	Jan 07 05:22 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '25	Sale	12.18	9,557	116,404	87,666	Jan 07 05:20 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '25	Sale	12.18	6,502	79,194	59,878	Jan 07 05:20 PM
LEONARD JOHN M	President and CEO	Jan 03 '25	Sale	12.18	26,807	326,509	941,115	Jan 07 05:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '25	Sale	12.18	8,966	109,206	77,388	Jan 07 05:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '25	Sale	12.18	7,422	90,400	64,048	Jan 06 04:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 02 '25	Sale	12.03	556	6,689	71,470	Jan 06 04:16 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '24	Sale	19.01	2,012	38,248	47,012	Oct 04 05:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience